The removal of 5 pharmaceuticals from the market in a
12-month period because of unexpected adverse events raised concerns
about the adequacy of the drug review process at the US Food and Drug
Administration (FDA). Specifically, concerns were raised about
improvements in drug review efficiency that significantly reduced FDA
review times. We have reviewed the circumstances of the 5 removals to
determine whether there was any relationship to the increased
efficiencies in the drug review process. When the removed drugs were
analyzed by date of approval, no increase in the number of drugs taken
off the market was seen, demonstrating that reduced review processing
time was not the reason for the cluster of removals. We conclude that
the agency's drug review procedures and postmarketing surveillance
system after a drug has been marketed are currently adequate but must
continually adjust to future challenges.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 128
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.